FDA Inspection
GlaxoSmithKline, LLC.GlaxoSmithKline, LLC. – FDA Inspection, Sep 25, 2024
Record Details
This FDA Inspection record concerns GlaxoSmithKline, LLC., with an inspection on September 25, 2024, issued by the Philadelphia District Office, covering human drugs.
View Company Profile
ID · a2084345-5a0c-4a87-8363-0d2bd8669d45
Inspection Facts
- Inspection number
- 1261906
- FDA center
- Human Drugs
Other FDA inspections of GlaxoSmithKline, LLC.
6| Date | Classification | Office | Project area |
|---|---|---|---|
| July 15, 2026 | Not classified | Philadelphia District Office | |
| March 7, 2025 | Not classified | Philadelphia District Office | |
| June 20, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 26, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 8, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for GlaxoSmithKline, LLC.
- FDA Inspection 1332910 - 2026-07-15
- FDA Inspection 1274978 - 2025-03-07
- FDA Inspection 1211050 - 2023-06-20
- FDA Inspection 1043309 - 2018-01-26
- FDA Inspection 927643 - 2015-05-08
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.